St Vincent's Institute of Medical Research

What St Vincent's Institute of Medical Research does

St Vincent's Institute of Medical Research (SVI) is a nonprofit medical research institute established in 1951 and headquartered at 9 Princes Street in Fitzroy, Victoria, Australia. The institute conducts discovery and translational research into the cause, prevention, and treatment of diseases with major health impact, with active programs spanning cancer, type 1 diabetes, immunology, DNA repair, gene editing, infectious disease, healthy ageing, regenerative medicine, and human genomics and evolution. SVI operates specialized laboratories (Genome Stability, DNA Repair & Recombination, Human Genomics & Evolution, Islet Biology, Immunology) and runs clinical programs including the Tom Mandel Islet Transplant Program (over 100 transplants performed since 2006) and the BANDIT trial of JAK inhibitor baricitinib in type 1 diabetes (results published in the New England Journal of Medicine in 2023). Technology assets include pioneering Prime Editing methods for bone marrow failure syndromes, mRNA-based gene editing delivery with over 10x efficiency versus DNA-based systems, and the BRAIx AI breast cancer risk tool published in The Lancet Digital Health.

The institute's business model is nonprofit and grant-dependent: revenue is generated from NHMRC competitive research grants (recent disclosed tranches totaling over $19M), philanthropic donations including the over-$8M Discovery Fund endowment and Catalyst Circle equipment program, major gifts from foundations such as the Ian Potter Foundation, and event-based fundraising (SVI Golf Day raising $110K). SVI monetizes research infrastructure through its wholly aligned Effica Biolabs contract research organization, which provides bespoke preclinical services for immune-related diseases to pharma and biotech clients, and the ATIC clinical trials network across Australia and New Zealand. As a founding partner of the Aikenhead Centre for Medical Discovery (ACMD) with six academic and hospital partners, SVI shares in a $206M biomedical engineering facility (4,500 sqm, 31 labs, capacity for 900 researchers) that opened on 10 June 2026. SVI does not sell commercial products; its end beneficiaries are Australian patients with cancer, diabetes, heart disease, and rare genetic disorders, served indirectly through research outputs, clinical trials, and the islet transplant program.

Name

St Vincent's Institute of Medical Research

Legal name

St Vincent's Institute of Medical Research

Website

https://svi.edu.au

Company type

Private

Founded year

1951

Operating status

Operating

Headcount range

101–250 employees

Short description

St Vincent's Institute of Medical Research (SVI) is a nonprofit Australian medical research institute founded in 1951, conducting translational research on cancer, type 1 diabetes, DNA repair, gene editing, and immunology, and serving Australian patients through clinical trials and the islet transplant program.

Ownership category

akta.pro rank

Product category

Medical Research

NAICS

Scientific Research and Development Services (5417), Testing Laboratories and Services (54138)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Medical research services
• Cancer research
• Diabetes research
• Immunology research
• Biomedical engineering

Headquarters

HQ city

Fitzroy

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Philanthropic donations: Tax-deductible donations from individuals supporting medical research, including major gifts, recurring donations, and bequests
2. Government research grants: Funding from National Health and Medical Research Council (NHMRC), including $5 million NHMRC Synergy Grant and investigator grants
3. Discovery Fund endowment: Long-term endowment fund valued at over $8 million providing annual funding for research, recruiting scientists and purchasing equipment
4. Catalyst Circle equipment donations: Donations specifically directed to acquiring cutting-edge equipment and technologies for research

Distribution channels1 record

Marketing channels5 records

Core offering

SVI is a nonprofit medical research institute that investigates the cause, prevention, and treatment of diseases including cancer, type 1 diabetes, heart disease, infectious diseases, and age-related conditions. Its deliverable outputs are laboratory research, clinical trials, and translational platforms, anchored by the Aikenhead Centre for Medical Discovery (ACMD) biomedical engineering facility and the Effica Biolabs contract research organization. The institute monetizes its science via government grants (NHMRC), philanthropic donations, and limited contract research services to pharmaceutical and biotechnology clients.

Product overview

St Vincent's Institute of Medical Research (SVI) is a medical research institute focused on discovering new knowledge to improve health outcomes. SVI operates as a collection of specialized research laboratories and services rather than a unified product platform. The Institute's main offerings include the Aikenhead Centre for Medical Discovery (ACMD) - a state-of-the-art biomedical engineering facility, Effica Biolabs - a contract research organization for preclinical testing, and various research platform services including flow cytometry, biobanking, and imaging. SVI's research spans multiple disease areas including cancer, diabetes, immunology, and infectious diseases, supported by clinical trials such as the BANDIT trial for type 1 diabetes.

Differentiator

Problem solved

Functional benefit

Brands

• Effica Biolabs: A contract research organisation offering bespoke preclinical services testing the therapeutic potential of drugs and devices for immune-related diseases, particularly type 1 diabetes.
• ATIC (Australasian Type 1 Diabetes Immunotherapy Collaborative)

Products and services

• Effica Biolabs A contract research organization offering bespoke preclinical services testing the therapeutic potential of drugs and devices for immune-related diseases, particularly type 1 diabetes. Provides animal disease models and human tissue assays to pharmaceutical and biotechnology clients.
• Research Platforms and Services Shared research infrastructure services including flow cytometry, mass spectrometry, micro-CT imaging, biobanking, and ion exchange filters supporting medical research activities.
• Tom Mandel Islet Transplant Program Clinical islet transplant service for patients with type 1 diabetes and severe hypoglycemic unawareness, integrated with SVI's immunology research program.
• ATIC Clinical Trials Network Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC) - a clinical trials network of adult and paediatric endocrinologists, immunologists, clinical triallists and members of the type 1 diabetes community across Australia and New Zealand, accelerating delivery of immunotherapy for type 1 diabetes.

Quantifiable outcome

• BRAIx AI tool published in The Lancet Digital Health demonstrates superior breast cancer risk prediction
• +3 more outcomes

Segments2 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• St Vincent's Hospital MelbournecoreStrategic or Co-development Partner · 10 June 2026SVI is a founding partner of the Aikenhead Centre for Medical Discovery (ACMD) along with St Vincent's Hospital Melbourne, located in the St Vincent's Fitzroy Health and Innovation Precinct. This partnership brings together researchers, engineers, clinicians and industry partners under one roof to accelerate translation of research into new technologies, treatments and healthcare solutions.
• Australian Catholic UniversitycoreStrategic or Co-development Partner · 10 June 2026Partner in the $206 million Aikenhead Centre for Medical Discovery (ACMD), contributing to the multidisciplinary environment designed to address pressing healthcare challenges through collaboration between researchers, engineers, clinicians and industry.
• Bionics InstitutecoreStrategic or Co-development Partner · 10 June 2026Partner in the Aikenhead Centre for Medical Discovery (ACMD), working collaboratively with SVI and other founding partners to accelerate medical innovation and translation of research to patient care.
• RMIT UniversitycoreStrategic or Co-development Partner · 10 June 2026Academic partner in the Aikenhead Centre for Medical Discovery (ACMD), bringing engineering expertise and research capabilities to the collaborative biomedical engineering centre.
• Swinburne University of TechnologycoreStrategic or Co-development Partner · 10 June 2026Academic partner in the Aikenhead Centre for Medical Discovery (ACMD), contributing to the multi-disciplinary research environment designed to accelerate translation of discoveries into healthcare solutions.
• University of MelbournecoreStrategic or Co-development Partner · 10 June 2026Academic partner in the Aikenhead Centre for Medical Discovery (ACMD), bringing significant research expertise to the partnership focused on translating medical research into real-world healthcare solutions.
• Children's Medical Research Institute (CMRI)coreStrategic or Co-development Partner · 7 January 2026SVI researchers Associate Professor Andrew Deans and Dr Sarah Henrikus are key contributors to a national $5 million NHMRC Synergy Grant program led by Professor Hilda Pickett at CMRI, targeting treatment-resistant ALT-dependent cancers.
• University of SydneycoreStrategic or Co-development Partner · 7 January 2026The national ALT-dependent cancers research program is administered through the University of Sydney, with SVI and CMRI as delivery partners, working to develop the first targeted treatments for these aggressive cancers.
• University of WollongongcoreStrategic or Co-development Partner · 7 January 2026Partner in the national ALT-dependent cancers research program, collaborating with SVI, CMRI, and University of Sydney to develop targeted treatments for treatment-resistant cancers.
• Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC)coreStrategic or Co-development PartnerSVI leads ATIC, a clinical trials network of adult and paediatric endocrinologists, immunologists, clinical triallists and members of the type 1 diabetes community across Australia and New Zealand, accelerating delivery of immunotherapy for type 1 diabetes.
• Effica Biolabs clientsminorImplementation/ SI/ Consulting PartnerContract research organization offering preclinical testing services to pharma and biotech companies, with close networks with service providers to complement and expand experimental design and testing needs.
• Nanyang Technological University (Singapore)minorStrategic or Co-development PartnerFormer institution of Associate Professor Irene Gallego Romero who served as Nanyang Assistant Professor before joining SVI, maintaining potential for ongoing research collaboration.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Walter and Eliza Hall Institute of Medical Research (WEHI): Australia's oldest medical research institute, located in Melbourne, focused on cancer, immune health, and infectious disease. Directly comparable to SVI in scale, scope, and funding model (NHMRC, philanthropy), and shares multiple personnel lineages with SVI.
• Baker Heart and Diabetes Institute: Melbourne-based nonprofit research institute specializing in cardiovascular and metabolic disease. Closely aligned with SVI's diabetes and heart disease programs, sharing clinical translation focus and NHMRC funding model.
• Garvan Institute of Medical Research: Sydney-based medical research institute focused on genomics, cancer, diabetes, and immunology. Comparable in scale, technology platforms (genomics/AI), and research translation approach to SVI.
• Peter MacCallum Cancer Centre: Australia's leading standalone cancer hospital and research centre. Andrew Deans completed his PhD here; SVI's Genome Stability and DNA Repair programs are closely related to Peter Mac's translational cancer research focus.
• Children's Medical Research Institute (CMRI): Active partner with SVI on the $5M NHMRC Synergy Grant for ALT-dependent cancer research. Similar nonprofit model with shared investigators (Andrew Deans, Sarah Henrikus) and a comparable research portfolio in genome stability and cancer.
• Hudson Institute of Medical Research: Melbourne-based medical research institute focused on cancer, infection, and women's and infant health. Comparable scale, structure, and translational research mission to SVI.
• Centenary Institute: Sydney-based nonprofit medical research institute focused on cancer, inflammation, and cardiometabolic disease. Similar funding model and disease-area overlap with SVI's immunology and cancer programs.
• Harry Perkins Institute of Medical Research: Western Australia-based medical research institute covering cancer, heart disease, and genetic diseases. Compares to SVI in scope, NHMRC reliance, and translational research positioning.
• QIMR Berghofer Medical Research Institute: Queensland-based large medical research institute with programs in cancer, infectious disease, and chronic disorders. Similar institute scale, government grant reliance, and translational pipeline to SVI.
• Murdoch Children's Research Institute (MCRI): Large Melbourne-based pediatric medical research institute affiliated with the Royal Children's Hospital. Comparable institute scale, NHMRC/PHRP grant structure, and clinical translation model to SVI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/SVIResearch
• Facebookfacebook.com/SVIResearch
• LinkedInlinkedin.com/company/st-vincents-institute

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about St Vincent's Institute of Medical Research